【摘要】 目的观察阿托伐他汀对老年非缺血性心力衰竭患者血浆肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)和Ⅰ型胶原羧基端交联肽(CITP)水平的影响,探讨他汀类药物减少或延缓老年非缺血性心力衰竭发生和发展的可能机制。方法选择经冠状动脉造影证实的老年非缺血性心力衰竭患者38例作为研究对象,随机分为他汀类治疗组(阿托伐他汀10mg/d)及常规治疗组,每组19例。随访6个月,测定治疗前后患者血清TNF-α、IL-6、MMP-9和CITP的水平,并通过超声心动图观察治疗前后左心室射血分数(LVEF)及左心室大小。结果治疗过程中有1例患者因转氨酶增高停用阿托伐他汀治疗。2组治疗后血清TNF-α、IL-6、MMP-9和CITP水平与治疗前相比均下降(P<0.05)。治疗后治疗组血清TNF-α、IL-6、MMP9和CITP水平及LVEF明显低于对照组(P<0.01)。结论阿托伐他汀可以降低非缺血性心力衰竭患者血清TNF-α、IL-6、MMP-9和CITP的水平,延缓老年非缺血性心力衰竭的发生发展。更多还原

【Abstract】 Objective To observe the effect of atorvastain on serum levels of tumor necrosis factor a(TNF-α),interleukin 6(IL-6),matrix metalloproteases-9(MMP-9)and carboxy terminal telopeptide of collagen type Ⅰ(CITP)in patients with non-ischemic heart failure,and to investigate the possible mechanism of HMG-COA reductase inhibitor to improve cardiac function in patients with non-ischemic heart failure.Methods Thirty-eight patients with non-ischemic heart failure identified by angiography were divided into atorvastain treatment group and rountine treatment group.The serum levels of TNF-α,IL-6,MMP-9 and CITP were examined and left ventricular ejection(LVEF)fraction and left ventricular end-diastolic dimension(LVEDD)were measured by echocardiography before and six months after treatment.Results The serum levels of TNF-α,IL-6,MMP-9 and CITP in both groups after treatment were significant lower than those before treatment(P<0.05).After treatment the serum levels of TNF-α,IL-6,MMP-9,CITP and LVEF in atorvastain treatment group were significantly lower than those in rountine treatment(P<0.01).Conclusion Atorvastain can improve cardiac function in patients with non-ischemic heart failure by decreasing the serum levels of TNF-α,IL-6,MMP-9 and CITP.更多还原